30
Participants
Start Date
September 1, 2025
Primary Completion Date
July 1, 2027
Study Completion Date
July 1, 2027
Suvorexant (dual orexin receptor antagonist)
Veteran patients with Major Depressive Disorder and elevated risk of suicide will receive the FDA-approved drug Suvorexant (brand name: Belsomra), a dual orexin receptor antagonist, for four weeks. Participants will take 10mg of Surovexant nightly for the first two weeks and 20mg of Surovexant nightly for the second two weeks.
RECRUITING
James J. Peters Veterans Affairs Medical Center, The Bronx
James J. Peters Veterans Affairs Medical Center
FED
Marianne Goodman
OTHER